Upgrade to SI Premium - Free Trial

Form 3 ANAVEX LIFE SCIENCES For: May 04 Filed by: Kellmeyer Terrie

May 14, 2026 4:16 PM
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
Kellmeyer Terrie
(Last) (First) (Middle)
630 5TH AVENUE
20TH FLOOR
(Street)
NEW YORK NY 10111
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/04/2026 		3. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Interim CEO
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to Buy) (1) 11/30/2033 Common Stock 46,668 7.21 D
Options (Right to Buy) (2) 02/20/2034 Common Stock 7,500 5.36 D
Options (Right to Buy) (3) 03/31/2035 Common Stock 50,000 8.58 D
Explanation of Responses:
1. Includes 35,001 fully vested options and 11,667 unvested options that will vest in two substantially equal tranches on June 30, 2026 and September 30, 2026.
2. Includes 2,500 fully vested options and 5,000 options which will vest in two equal tranches based on two performance milestones.
3. Includes 25,000 fully vested options and 25,000 options which will vest in two equal tranches based on two performance milestones.
/s/ Terrie Kellmeyer 05/14/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings